HomeAbout

TL;DR CNBC


Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - TL;DR CNBC

Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet

Publishing timestamp: 2024-04-23 12:57:10


Summary

Biotech IPO market showed signs of life in the first quarter of 2024, with nine companies collectively raising more than $1.3 billion. However, the market is still uncertain and may not fully recover. The performance of recent IPOs and the Federal Reserve's decision on interest rates will play a significant role in shaping the future of biotech IPO activity. Anesthesiologists are using virtual reality and artificial intelligence to improve medical education and clinical practice within their specialty.


Sentiment: NEUTRAL

Tickers: GUTSUNDEFINEDCTNMUNH

Keywords: biotech and pharmaceuticalschromocell therapeutics corpmetagenomi inchealth care industryalto neuroscience incscienceentertainmentfractyl health inckyverna therapeutics inctelomir pharmaceuticals inccg oncology incbusiness newsunitedhealth group incarrivent biopharma incboundless bio inccontineum therapeutics inc

Source: https://www.cnbc.com/2024/04/23/healthy-returns-biotech-ipos-heated-up-but-havent-fully-recovered.html


Developed by Leo Phan